In 2036, you will be glad you bought these ASX shares today

Want to make long term investments? I think these shares could be top picks.

Key points
  • Lovisa's global expansion and scalable fast-fashion jewellery concept offer potential long-term growth, fuelled by its ability to replicate success across various markets with strong returns.
  • Telix Pharmaceuticals is transitioning from a speculative biotech to a revenue-generating force in radiopharmaceuticals, poised to capitalise on growing demand for cancer diagnostics, despite recent regulatory challenges.
  • Temple & Webster's online-only model and digital disruption strategy could secure long-term gains as it capitalises on the shift towards e-commerce in the traditionally offline furniture market.

I'm a big fan of buy and hold investing and believe it is one of the best ways to grow wealth.

But which ASX shares could be worth buying and holding for the long term? Let's take a look at three that I think could be wealth generators over the next decade. They are as follows:

A man points at a paper as he holds an alarm clock, indicating the ex-dividend date is approaching.

Image source: Getty Images

Lovisa Holdings Ltd (ASX: LOV)

Lovisa is a great example of how powerful a simple concept can become when executed well. What began as a fast-fashion jewellery retailer in Australia has evolved into a global roll-out machine, with over a thousand stores now operating across the world.

The real attraction here is its scalability. Lovisa's store economics have proven repeatable across geographies, allowing it to expand aggressively while still generating strong returns on capital. Unlike many retailers, it carries limited fashion risk due to its low price point and fast inventory turnover, which keeps customers coming back regularly.

If Lovisa can continue executing its international expansion strategy over the next decade, today's footprint could look very small in hindsight.

Telix Pharmaceuticals Ltd (ASX: TLX)

Another ASX share that could be a top option for buy and hold investors is Telix Pharmaceuticals.

It offers exposure to a completely different growth driver. That is the global healthcare and diagnostics market. Telix specialises in radiopharmaceuticals, which are used to detect and treat cancer with far greater precision than traditional methods.

What makes Telix attractive is that it has already crossed an important threshold. It has moved beyond being a purely speculative biotech and into a commercial phase, with approved products generating growing revenue, while a broader pipeline continues to advance.

Unfortunately, it has not been plain sailing this year, with the US FDA knocking back applications. However, management appears confident it will be able to gain approval next year after responding to the regulator's concerns.

In light of this, with demand for cancer diagnostics and targeted therapies is only expected to grow, now could be an opportune time to buy Telix shares while they are trading down near their 52-week low.

Temple & Webster Group Ltd (ASX: TPW)

Finally, Temple & Webster is a classic long-term digital disruption story. It operates in a category that has been slow to move online, giving it a significant opportunity to keep taking market share as consumer behaviour evolves.

Unlike traditional furniture retailers, Temple & Webster benefits from a capital-light, online-only model. This gives it flexibility and operating leverage as volumes grow.

And with online penetration in the Australian furniture market still much lower than in other Western markets, the next 10 years could be very fruitful for Temple & Webster and materially change the scale of the business.

Motley Fool contributor James Mickleboro has positions in Lovisa and Temple & Webster Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Lovisa, Telix Pharmaceuticals, and Temple & Webster Group. The Motley Fool Australia has recommended Lovisa, Telix Pharmaceuticals, and Temple & Webster Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Ascending piles of coins and plants in three jars, with a hand putting a coin in the first jar.
Growth Shares

A rare buying opportunity in 1 of Australia's top shares?

This stock is an ASX leader and it looks like one of Australia’s top shares.

Read more »

Two smiling colleagues looking at a tablet in a data centre.
Growth Shares

Will Goodman shares reach $30 in 2027?

I look at the earnings forecasts to see how realistic a move back to this level could be.

Read more »

Two brokers analysing the share price with the woman pointing at the screen and man talking on a phone.
Growth Shares

2 ASX shares highly recommended to buy: Experts

These businesses could be undervalued and deliver good returns.

Read more »

Woman pointing to a hologram of a world map with finance graphs and related themes.
Growth Shares

Down over 50%: 2 ASX shares to buy for global growth

Both companies are building global momentum. Patient investors should watch.

Read more »

Hand putting coins in a glass jar that says retirement, with a retro alarm clock on the other side, and piles of increasing coins in the middle.
Growth Shares

2 top ASX shares to buy and hold for the next decade

I think these ASX shares have a great future!

Read more »

Red buy button on an Apple keyboard with a finger on it.
Growth Shares

2 ASX shares tipped to surge 70% or more in the next 12 months

Analysts are excited about these stocks…

Read more »

Couple using their digital tablet together.
Growth Shares

Codan vs Pro Medicus: Which ASX growth stock is better value?

Codan and Pro Medicus are both ASX growth stars, but which one offers better value for investors right now? I…

Read more »

Woman enjoying listening to music on her headphones.
Growth Shares

3 ASX 200 shares I'd buy and hold for a decade

I take a closer look at three shares with plenty of room to grow over the next decade.

Read more »